AstraZeneca PLC (AZN)

業務介紹

阿斯利康公司(AstraZeneca PLC)是一家生物製藥公司,專注於處方藥物的發現、開發、製造和商業化。其上市產品包括:

腫瘤科:Calquence、Enhertu、Faslodex、Imfinzi、Iressa、Koselugo、Lumoxiti、Lynparza、Orpathys、Tagrisso和Zoladex。

心血管、腎臟和代謝疾病:Brilinta/Brilique、Bydureon/Byetta、BCise、Byetta、Crestor、Evrenzo、Farxiga/Forxiga、Komboglyze/Kombiglyze XR、Lokelma、Onglyza、Qtern和Xigduo/Xigduo XR。

呼吸和免疫:Bevespi Aerosphere、Breztri Aerosphere、Daliresp/Daxas、Duaklir Genuair、Fasenra、Pulmicort、Saphnelo、Symbicort和Tudorza/Eklira/Bretaris。

罕見疾病:Andexxa/Ondexxya、Kanuma、Soliris、Strensiq和Ultomiris。

其他產品包括Synagis(呼吸道合胞病毒)、Fluenz Tetra/FluMist Quadrivalent(流感)、Seroquel IR/Seroquel XR(精神分裂症雙相障礙)、Nexium和Losec/Prilosec(胃腸疾病),以及Vaxzevria和Evusheld(COVID-19)。

該公司通過分銷商和當地代表辦事處在英國、歐洲其他地區、美洲、亞洲、非洲和澳大拉西亞提供服務。它與Regeneron Pharmaceuticals、Neurimmune AG、Ionis Pharmaceuticals、Proteros Biostructures和Sierra Oncology有合作協議。該公司原名Zeneca Group PLC,於1999年4月更名為AstraZeneca PLC,於1992年註冊成立,總部位於英國劍橋。



AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

公司網址

https://www.astrazeneca.com